Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Xu discussed the benefit of using biomarkers to more precisely guide treatment for patients with renal cell carcinoma.

The incidence of hepatocellular carcinoma has risen between 2010 and 2019; however, for people under 50 years of age, the proportion of cases has declined.

I wrote a poem about life with endometrial cancer, rejecting pity and embracing strength, connection and the dignity of being ...

Dena Paluck became a mentor to other parents after guiding her daughter through osteosarcoma treatment and feeling isolated ...

Among individuals who receive a cancer diagnosis, entering into the survivorship period can be one of the most ...

I survived peritoneal mesothelioma thanks to the love, prayers, and support of family, friends, and strangers who reminded me ...

In a phase 3 trial, 72.2% of patients with recurrent low-grade bladder cancer kept complete response at 24 months after ...